DETECTION OF REVERSAL OF AN ANTICOAGULANT USING ECARIN AND FACTOR XA CLOTTING ASSAYS

摘要

In some embodiments, the invention provides a method for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient. The method includes subjecting a control sample of a control blood component (known not to contain the anticoagulant), to a clotting assay in the presence of a Factor Xa reagent to obtain a control Factor Xa clotting measurement; and subjecting a sample of a blood component from the patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient Factor Xa clotting measurement, wherein the clotting measurement of the patient sample greater than the clotting measurement of the control sample indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient. In some embodiments, the invention further includes a method for classifying the anticoagulant as an anti-Factor Xa anticoagulant or a Direct Thrombin Inhibitor anticoagulant using a clotting assay in the presence of an ecarin reagent.;In some embodiments, the invention provides a method for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient. The method includes subjecting a control sample of a control blood component (known not to contain the anticoagulant), to a clotting assay in the presence of an ecarin reagent to obtain a control ecarin measurement; and subjecting a sample of a blood component from the patient suspected of having the anticoagulant to the clotting assay in the presence of the ecarin reagent to obtain a patient ecarin clotting measurement, wherein the clotting measurement of the patient sample greater than the clotting measurement of the control sample indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient and classifies it as a DTI. In some embodiments, the invention further includes a method for identifying and classifying the anticoagulant as an anti-Factor Xa anticoagulant in the presence of a Factor Xa reagent.